SLC7A2

Across TCGA pan-cancer cohorts, SLC7A2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC7A2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SLC7A2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC7A2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM and LUAD are the cancer types where SLC7A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.522	0.208	.034	3	view →
LUAD	DFS	Quartile	II,III,IV	0.570	0.943	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SLC7A2–GBM (DFS)

Open the GBM breakdown →